Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Covid19
Interventions
DRUG

Transfusion of COVID-19 convalescent plasma

Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient

Trial Locations (1)

75012

SMIT, Saint Antoine hospital, Paris

All Listed Sponsors
collaborator

Etablissement Français du Sang

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04345991 - Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort | Biotech Hunter | Biotech Hunter